SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
၉.၁၈ US$
arrow_upward
+၀.၅၅%(+၀.၀၅၀) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SGIOY...
Open
၉.၃၆ US$
High
၉.၃၆ US$
Low
၉.၁၈ US$
Mkt. cap
ဋေ ၂.၆၁ သိန်း
Avg. vol.
၁.၇၅ သိန်း
Volume
၁.၆၄ သိန်း
52-wk high
၁၂.၀၀ US$
52-wk low
၇.၈၃ US$
Beta
၀.၀၇
Shares outstanding
၁၇၇.၉၃ ဋေ
No. of employees
၆ ထောင်
Open
၉.၃၆ US$
High
၉.၃၆ US$
Low
၉.၁၈ US$
Mkt. cap
ဋေ ၂.၆၁ သိန်း
Avg. vol.
၁.၇၅ သိန်း
Volume
၁.၆၄ သိန်း
52-wk high
၁၂.၀၀ US$
52-wk low
၇.၈၃ US$
Beta
၀.၀၇
Shares outstanding
၁၇၇.၉၃ ဋေ
No. of employees
၆ ထောင်
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁၃ နာရီ
Shionogi schedules October 29 results for Shionogi stock
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs